FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:192-193 July 20, 1995 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Kovacs, J. A.

To the Editor: The article by Kovacs et al. on interleukin-2 therapy in patients with human immunodeficiency virus (HIV) infection (March 2 issue)¹ highlights the dilemma that this disease poses: how to get rid of a virus whose replication is enhanced by activation of the immune system.

The increase in the HIV RNA level after an infusion of interleukin-2 was most consistent in patients with CD4 counts of 200 or fewer cells per cubic millimeter. In this group, interleukin-2 was associated with "few immunologic improvements, and substantial toxic effects," but increased levels of HIV RNA were also observed in patients . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.